Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$15.53 USD

15.53
165,234

+0.19 (1.24%)

Updated Apr 19, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum

by Zacks Equity Research

Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the Week article.

Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

Tirthankar Chakraborty headshot

5 Stocks to Keep a Tab on for Solid Earnings Acceleration

by Tirthankar Chakraborty

Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).

Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Catalyst's (CPRX) Q1 Earnings Lag, Sales Boost Revenues

by Zacks Equity Research

Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%.

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $16.60, moving -0.12% from the previous trading session.

Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.

Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $15.76, marking a -1.62% move from the previous day.

3 Reasons Growth Investors Will Love Catalyst (CPRX)

by Zacks Equity Research

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed at $16.52 in the latest trading session, marking a +0.24% move from the prior day.

Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.82, moving -1.44% from the previous trading session.

Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

by Zacks Equity Research

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Rebounds in 2023

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.

Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.78, marking a -0.94% move from the previous day.

Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPSE

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

by Zacks Equity Research

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock

by Zacks Equity Research

Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays

by Zacks Equity Research

Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.